Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protein yippee-like 4 (YPEL4) is a member of the highly conserved YPEL gene family, encoding proteins with zinc-finger-like domains known as Yippee domains[1]. YPEL4 is localized to the centrosome during interphase and to the mitotic apparatus during mitosis, suggesting an essential role in cell cycle regulation and proliferation[1]. YPEL4 interacts with major vault protein (MVP) and participates in mitogen-activated protein kinase (MAPK) pathway signaling, influencing Elk-1-mediated transcription and cellular proliferation[1]. It is highly expressed in lung, heart, and especially in late-stage erythroid differentiation[2][3]. YPEL4 deficiency in mice causes abnormal red blood cell morphology, reduced membrane deformability, and secondary polycythemia[2][3]. The protein may also play roles in the development of pulmonary diseases and is implicated in several cancers[1]. Despite its biological importance, YPEL4 is not yet associated with any approved drugs or established clinical biomarkers, and its potential as a therapeutic target is under investigation[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protein yippee-like 4 (YPEL4).